Keyphrases
Serum Concentration
100%
Inflammatory Bowel Disease
100%
Secondary Loss of Response
100%
Antibodies to Infliximab
100%
Infliximab
50%
Loss of Response
43%
Ulcerative Colitis
12%
Crohn's Disease
12%
Dynamic Parameters
12%
Static Parameters
12%
Infliximab Therapy
12%
Germany
6%
Therapeutic Decision-making
6%
Outpatient Clinic
6%
Significant Risk Factors
6%
Predictive Power
6%
Maintenance Interval
6%
Therapy Success
6%
C-reactive Protein
6%
Immunogenicity
6%
Level Dynamics
6%
Negative Slope
6%
Maintenance Therapy
6%
Cox Regression
6%
Positive Slope
6%
Diagnostic Predictors
6%
Fecal Calprotectin
6%
Infliximab Levels
6%
Base-of-slope
6%
Immunology and Microbiology
Dynamics
100%
Blood Level
100%
Infliximab
100%
Inflammatory Bowel Disease
100%
Crohn's Disease
7%
Ulcerative Colitis
7%
Immunogenicity
3%
C-Reactive Protein
3%
Nursing and Health Professions
Blood Level
100%
Inflammatory Bowel Disease
100%
Infliximab
100%
Ulcerative Colitis
7%
Outpatient Department
3%
Patient with Inflammatory Bowel Disease
3%
Proportional Hazards Model
3%
Diagnosis
3%
C Reactive Protein
3%
Patient with Crohn's Disease
3%
Maintenance Therapy
3%
Calgranulin
3%
Crohn's Disease
3%
Biochemistry, Genetics and Molecular Biology
Dynamics
100%
Blood Level
100%
Infliximab
100%
Retrospective Study
3%
Immunogenicity
3%
Calgranulin
3%
C-Reactive Protein
3%
Medicine and Dentistry
Inflammatory Bowel Disease
100%
Infliximab
100%
Ulcerative Colitis
7%
Diagnosis
3%
Crohn's Disease
3%
Outpatient
3%
Retrospective Study
3%
C Reactive Protein
3%
Patient with Crohn's Disease
3%
Proportional Hazards Model
3%
Maintenance Therapy
3%
Patient with Inflammatory Bowel Disease
3%
Faecal Calprotectin
3%
Immunogenicity
3%
Neuroscience
Infliximab
100%
Inflammatory Bowel Disease
100%
C-Reactive Protein
3%
Calgranulin
3%